GlobeNewswireMAY 73 min read$PHAR

Pharming Group announces presentations at CIS 2026 Annual

Pharming Group N.V. is presenting new data at the 2026 Annual Meeting of the Clinical Immunology Society, focusing on its drug leniolisib. Presentations will cover interim outcomes for leniolisib in pediatric APDS patients, clinical experience in CVID and CVID-like disorders, and insights into other primary immunodeficiencies. These presentations highlight the ongoing clinical trials and the company's commitment to advancing understanding and treatment of rare immunological conditions.

Original reporting

GlobeNewswire

Published May 7, 2026, 5:04 AM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai May 7, 2026, 5:30 AM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

Pharming Group announces presentations at CIS 2026 Annual — source image — Source · GlobeNewswire

Decision brief

The 30-second read

$PHARBullishMed

Why it matters

The presentation of new data at a reputable conference can serve as a catalyst for stock appreciation.

Market read

The event is highly relevant for biotech investors, especially those focusing on immunology and rare diseases.

What to watch

Potential delays in clinical trial outcomes or negative data disclosures could negate positive sentiment.

Timing: Immediate, as the event occurs shortly after publication date.

Background

Pharming Group is a biotech company focusing on rare immunological diseases, with ongoing clinical trials for leniolisib.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$PHARBullishHigh confidence

Context

High relevance due to positive sentiment and ongoing clinical developments.

Expected impact

Moderate upward movement in PHAR stock price over the short to medium term.

Evidence & confidence

The positive clinical data and active engagement in scientific forums can enhance the company's reputation and investor sentiment, likely leading to increased stock demand.

Market effects

Sector

Potential positive impact on the life sciences and biotech sectors due to advancements in immunology treatments.

Regional

Limited regional impact; primarily affects investors and stakeholders in the biotech industry.

Global

Moderate; advances in rare disease treatments can influence global biotech investment trends.

Counterpoint

What could challenge this read

Some skeptics may argue that clinical trial data may not translate into immediate stock gains due to regulatory hurdles or market skepticism.

Key entities

Company
Pharming Group N.V.
A biotech firm specializing in rare disease treatments.
Drug
Leniolisib
A drug candidate for primary immunodeficiency syndromes.

Read at source ← All news

JUL 30

$PHARMedAI 8/10

Pharming Group cuts 2026 revenue guidance by $30m on weak sales By Investing.com

Pharming Group cut its 2026 revenue guidance by $30 million to $375 million to $395 million, citing weaker Q2 sales and continued weakness in its legacy Ruconest product. Q2 revenue was $90.2 million versus $100.8 million consensus. Ruconest sales fell 10% to $72.3 million, below $83.8 million. Operating profit was $1.3 million.

investing.com4 min

JUL 30

$PHARMedAI 8/10

Pharming Group N.V.: Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader ther

Pharming Group N.V. reported Q2 2026 total revenues of US$90.2m, down 3% year over year. RUCONEST revenue was US$72.3m, down 10% YoY, while Joenja (leniolisib) revenue rose to US$17.9m, up 40% YoY. Q2 operating profit fell to US$1.3m. The company revised 2026 revenue guidance to US$375m-395m and operating expense guidance to US$315m-320m.

finanznachrichten.de7 min

JUN 4

$BPMedAI 8/10

European Shares Edge Higher On Lebanon Ceasefire; FTSE 100 Dips As Energy Stocks Drag

European stocks rose slightly after Israel and Lebanon agreed to renew a fragile ceasefire, while oil prices fell more than 1% toward $96/bbl. STOXX 600 added 0.2% to 622.14; DAX +0.6% and CAC 40 +0.8%, but FTSE 100 -0.4% as BP and Shell dragged. Vivendi -4.6%; Remy Cointreau +11%; UMG -5.6%; CMC Markets +13%.

finanznachrichten.de4 min

JUN 4

$PHARMedAI 9/10

Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS

Pharming said the U.S. FDA accepted its resubmitted supplemental NDA for Joenja (leniolisib) to treat children ages 4–11 with APDS. After a Jan. 30, 2026 CRL and a March 26 Type A meeting, the sNDA seeks approval for 40 mg and 50 mg twice daily for patients ≥27 kg, with FDA requesting additional batch-testing analytical data. The PDUFA target action date is Oct. 24, 2026. A separate sNDA for lower-weight patients is planned for the second half of 2026.

manilatimes.net4 min

AUG 11

$PMed

Everpure Lands New Design Win with Second Top-Five Hyperscaler

Everpure (NYSE: P) said it secured a design win and supply agreement with a second top-five hyperscaler, building on a similar win announced in late 2024. The company attributes the deal to its DirectFlash technology for hyperscale storage. Everpure expects revenue contributions starting in fiscal 2028 and beyond.

itwire.com2 min